Determination of the marker of Alzheimer's disease and neurodegeneration, phosphorylated tau protein (pTau181) in the blood
Alzheimer's disease is the most common form of dementia, associated with the gradual destruction of nerve cells in the brain.
It leads to memory impairment, cognitive decline, and behavioral changes.
The disease develops slowly but progresses, significantly affecting the quality of life of the patient and their family.
In the early stages, the disease may manifest as:
- forgetfulness of recent events and names;
- difficulty concentrating;
- decreased ability to plan and make decisions;
- mood and behavior changes.
Over time, the symptoms intensify, leading to severe dementia and loss of independence.
One of the key biomarkers of Alzheimer's disease is phosphorylated tau protein 181 (pTau181).Tau protein is involved in maintaining the structure of neurons. In Alzheimer's disease, it undergoes pathological phosphorylation, leading to the formation of neurofibrillary tangles.
Elevated levels of pTau181 in the blood reflect neurodegenerative processes and are associated with amyloid pathology. The pTau181 test allows for the early detection of Alzheimer's disease, differentiation from other causes of dementia, and supports the physician in choosing the right treatment strategy.
Advantages of pTau181 test:
- A routine blood test without complicated procedures
- Fast results
- High clinical significance
- Possibility of early detection of the disease